Cargando…

Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma

Cholangiocarcinoma is an epithelial malignancy arising in the region between the intrahepatic bile ducts and the ampulla of Vater at the distal end of the common bile duct. The effect of current chemotherapy regimens against cholangiocarcinoma is limited, and the prognosis of patients with cholangio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakaoka, Toshiaki, Saito, Yoshimasa, Saito, Hidetsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485935/ https://www.ncbi.nlm.nih.gov/pubmed/28545228 http://dx.doi.org/10.3390/ijms18061111

Ejemplares similares

microRNA-34a as a Therapeutic Agent against Human Cancer
por: Saito, Yoshimasa, et al.
Publicado: (2015)

Inhibition of DNA Methylation Suppresses Intestinal Tumor Organoids by Inducing an Anti-Viral Response
por: Saito, Yoshimasa, et al.
Publicado: (2016)

Glucose Depletion Enhances the Stem Cell Phenotype and Gemcitabine Resistance of Cholangiocarcinoma Organoids through AKT Phosphorylation and Reactive Oxygen Species
por: Yoshikawa, Nao, et al.
Publicado: (2019)

Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system
por: Saito, Yoshimasa, et al.
Publicado: (2018)

Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
por: Micevic, Goran, et al.
Publicado: (2017)

Cluster microRNAs miR‐194 and miR‐215 suppress the tumorigenicity of intestinal tumor organoids
por: Nakaoka, Toshiaki, et al.
Publicado: (2017)

Aberrant DNA Methylation in Keratoacanthoma
por: Nobeyama, Yoshimasa, et al.
Publicado: (2016)

Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis
por: Yamada, Shoji, et al.
Publicado: (2017)

Publisher Correction: Epigenetic silencing of Lgr5 induces senescence of intestinal epithelial organoids during the process of aging
por: Uchida, Ryoei, et al.
Publicado: (2019)

Epigenetic silencing of Lgr5 induces senescence of intestinal epithelial organoids during the process of aging
por: Uchida, Ryoei, et al.
Publicado: (2018)

MicroRNAs in cancers and neurodegenerative disorders
por: Saito, Yoshimasa, et al.
Publicado: (2012)

Role of CTCF in the regulation of microRNA expression
por: Saito, Yoshimasa, et al.
Publicado: (2012)

Establishment and Long-Term Culture of Organoids Derived from Human Biliary Tract Carcinoma
por: Saito, Yoshimasa, et al.
Publicado: (2020)

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis – The promise of DNA methylation and molecular biomarkers
por: Vedeld, Hege Marie, et al.
Publicado: (2020)

Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?
por: Pietrobono, Silvia, et al.
Publicado: (2021)

Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma
por: Willemsen, Mathijs, et al.
Publicado: (2017)

Aberrantly methylated-differentially expressed genes and related pathways in cholangiocarcinoma
por: Lin, Guan, et al.
Publicado: (2022)

Generation of functional human hepatocytes in vitro: current status and future prospects
por: Yamaguchi, Tomoko, et al.
Publicado: (2019)

Aberrant DNA methylation in cervical Carcinogenesis
por: Yang, Hui-Juan
Publicado: (2013)

Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model
por: Yamada, Shoji, et al.
Publicado: (2018)

Aberrant DNA Methylation of ABC Transporters in Cancer
por: Zappe, Katja, et al.
Publicado: (2020)

Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity
por: Lozano, Elisa, et al.
Publicado: (2023)

Identification of therapeutic targets and prognostic biomarkers in cholangiocarcinoma via WGCNA
por: Xu, Lei, et al.
Publicado: (2022)

Field cancerization in the colon: a role for aberrant DNA methylation?
por: Luo, Yanxin, et al.
Publicado: (2014)

DNA Methylation: An Important Biomarker and Therapeutic Target for Gastric Cancer
por: Zeng, Yunqing, et al.
Publicado: (2022)

DNA Methylation as a Therapeutic Target for Bladder Cancer
por: Nunes, Sandra P., et al.
Publicado: (2020)

DNA Methylation Aberrant in Atherosclerosis
por: Dai, Yao, et al.
Publicado: (2022)

Role of DNA Methylation Profiles as Potential Biomarkers and Novel Therapeutic Targets in Head and Neck Cancer
por: Burkitt, Kyunghee
Publicado: (2023)

Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies
por: Acher, Alexandra W., et al.
Publicado: (2021)

Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma
por: Marin, Jose J.G., et al.
Publicado: (2020)

DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer
por: Letelier, Pablo, et al.
Publicado: (2012)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma
por: Andresen, Kim, et al.
Publicado: (2015)

An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma
por: Seeree, Pattaya, et al.
Publicado: (2015)

Biological Role and Aberrant Overexpression of Syntenin-1 in Cancer: Potential Role as a Biomarker and Therapeutic Target
por: Pintor-Romero, Valeria Guadalupe, et al.
Publicado: (2023)

Aberrant Methylation of LINE-1 Transposable Elements: A Search for Cancer Biomarkers
por: Ponomaryova, Anastasia A., et al.
Publicado: (2020)

microRNA-mediated resistance to hypoglycemia in the HepG2 human hepatoma cell line
por: Ueki, Satomi, et al.
Publicado: (2016)

Aberrant DNA Methylation and Prostate Cancer
por: Majumdar, Sunipa, et al.
Publicado: (2011)

Aberrant DNA Methylation in ES Cells
por: Ludwig, Guy, et al.
Publicado: (2014)

Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori
por: Saito, Yoshimasa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o30hg83cc36qcbu7ded9k8h3ih